Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples
Open Access
- 3 November 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
Abstract
Rationale: More than half of patients who receive thrombolysis for acute ischaemic stroke fail to recanalize. Elucidating biological factors which predict recanalization could identify therapeutic targets for increasing thrombolysis success. Hypothesis: We hypothesize that individual patient plasmin potential, as measured by in vitro response to recombinant tissue-type plasminogen activator (rt-PA), is a biomarker of rt-PA response, and that patients with greater plasmin response are more likely to recanalize early. Methods: This study will use historical samples from the Barcelona Stroke Thrombolysis Biobank, comprised of 350 pre-thrombolysis plasma samples from ischaemic stroke patients who received serial transcranial-Doppler (TCD) measurements before and after thrombolysis. The plasmin potential of each patient will be measured using the level of plasmin-antiplasmin complex (PAP) generated after in-vitro addition of rt-PA. Levels of antiplasmin, plasminogen, t-PA activity, and PAI-1 activity will also be determined. Association between plasmin potential variables and time to recanalization [assessed on serial TCD using the thrombolysis in brain ischemia (TIBI) score] will be assessed using Cox proportional hazards models, adjusted for potential confounders. Outcomes: The primary outcome will be time to recanalization detected by TCD (defined as TIBI >= 4). Secondary outcomes will be recanalization within 6-h and recanalization and/or haemorrhagic transformation at 24-h. This analysis will utilize an expanded cohort including similar to 120 patients from the Targeting Optimal Thrombolysis Outcomes (TOTO) study. Discussion: If association between proteolytic response to rt-PA and recanalization is confirmed, future clinical treatment may customize thrombolytic therapy to maximize outcomes and minimize adverse effects for individual patients.Funding Information
- National Health and Medical Research Council (APP1085550)
This publication has 11 references indexed in Scilit:
- Developing a multivariable prediction model for functional outcome after reperfusion therapy for acute ischaemic stroke: study protocol for the Targeting Optimal Thrombolysis Outcomes (TOTO) multicentre cohort studyBMJ Open, 2020
- Tissue Is More Important than Time in Stroke Patients Being Assessed for ThrombolysisFrontiers in Neurology, 2018
- Worse Outcome in Stroke Patients Treated with rt-PA Without Early Reperfusion: Associated FactorsTranslational Stroke Research, 2017
- Natural heterogeneity of α2-antiplasmin: functional and clinical consequencesBlood, 2016
- Perfusion computed tomography to assist decision making for stroke thrombolysisBrain, 2015
- Collateral Score Complements Clot Location in Predicting the Outcome of Intravenous ThrombolysisAmerican Journal of Neuroradiology, 2014
- Low Rates of Acute Recanalization With Intravenous Recombinant Tissue Plasminogen Activator in Ischemic StrokeStroke, 2010
- Desmoteplase-mediated plasminogen activation and clot lysis are inhibited by the lysine analogue tranexamic acidBlood Coagulation & Fibrinolysis, 2008
- Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PANeurology, 2005
- Thrombolysis in Brain Ischemia (TIBI) Transcranial Doppler Flow Grades Predict Clinical Severity, Early Recovery, and Mortality in Patients Treated With Intravenous Tissue Plasminogen ActivatorStroke, 2001